
|Articles|January 24, 2005
BREAKING NEWS...
The black eye the FDA received recently over its handling of Vioxx (rofecoxib, Merck) and antidepressants hasn't slowed the agency's new drug approval rate for 2004. It cleared 31 new molecular entities (NMEs) last year, up from 21 in 2003.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Once Weekly Oral HIV Regimen Maintains Suppression Through Week 48
2
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
3
ICER Report Finds GLP-1s Are Cost-Effective But Warns of Budget Strain
4
Postpartum Mothers Favor Bedtime Stopping Rule Over Stricter Chrononutrition Approaches
5




























